RRM2 and glioma: To explore the therapeutic potential of targeting the BRCA1-RRM2 signalling axis in malignant gliomas, we performed immunohistochemistry (IHC) analysis BRCA1 and RRM2 in 145 gliomas (Supplementary Table 2) and 10 non-neoplastic adult brain controls (NB).